PRESENTATION
Q4 2023 — Results presentation
Q4 2023PDF · 33 pages5.0 MB
-- 1 of 33 -- -- 2 of 33 -- -- 3 of 33 -- -- 4 of 33 -- -- 5 of 33 -- -- 6 of 33 -- -- 7 of 33 -- -- 8 of 33 -- -- 9 of 33 -- POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA Sum of Program Change Sum of Region Change Sum of Check Change Sum of Program Change Sum of Region Change Sum of Check Change Sum of Program Change Sum of Region Change Sum of Check Change Phase III OPSUMIT (macitentan) US OPSUMIT (macitentan) US SIMPONI (golimumab) TREMFYA (guselkumab) EU Pediatric Pulmonary Arterial Hypertension (TOMORROW) Pediatric Pulmonary Arterial Hypertension (TOMORROW) EU Pediatric Ulcerative Colitis Crohn's Disease (GALAXI) US OPSYNVI (macitentan/tadalafil STCT) UPTRAVI (selexipag) STELARA (ustekinumab) TREMFYA (guselkumab) EU Pulmonary Arterial Hypertension EU Pediatric Pulmonary Arterial Hypertension (SALTO) EU Pediatric Crohn's Disease Ulcerative Colitis Monotherapy (QUASAR) US EDURANT (rilpivirine) US nipocalimab US TREMFYA (guselkumab) RYBREVANT (amivantamab) EU HIV pediatric 2-12 year old EU Generalized Myasthenia Gravis Pediatric Psoriasis Subcutaneous (PALOMA-3) P US^ BALVERSA (erdafitinib) US RYBREVANT (amivantamab) US TREMFYA (guselkumab) ERLEADA (apalutamide) EU Urothelial Cancer (THOR) EU Subcutaneous (PALOMA-3) EU Crohn's Disease (GALAXI) High Risk Prostate Cancer (PROTEUS) US DARZALEX (daratumumab) US DARZALEX (daratumumab) US TREMFYA (guselkumab) seltorexant Frontline multiple myeloma transplant eligible (PERSEUS) EU Frontline multiple myeloma transplant eligible (PERSEUS) Pediatric Juvenile Psoriatic Arthritis Adjunctive treatment for major depressive disorder with insomnia symptoms US CARVYKTI (ciltacabtagene autoleucel) CABENUVA US TREMFYA (guselkumab) nipocalimab EU Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4) EU HIV Adolescents EU Ulcerative Colitis Monotherapy (QUASAR) Generalized Myasthenia Gravis US RYBREVANT (amivantamab) US TREMFYA (guselkumab) TREMFYA (guselkumab) EU Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON) Ulcerative Colitis Subcutaneous Induction (ASTRO) Crohn's Disease Subcutaneous Induction (GRAVITI) US RYBREVANT / lazertinib US TREMFYA (guselkumab) aticaprant EU Non Small Cell Lung Cancer 2L (MARIPOSA-2) EU Crohn's Disease Subcutaneous Induction (GRAVITI) Adjunctive Major Depressive Disorder US RYBREVANT / lazertinib Phase II EU Non Small Cell Lung Cancer (MARIPOSA) Combination Therapy Psoriatic Arthritis nipocalimab Sjogren's Disease TAR-200 (RIS/gemcitabine plus cetrelimab) Non Muscle Invasive Bladder Cancer Johnson & Johnson Innovative Medicine Pipeline Key Events in 2024* *This information is as of January 23, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. ^ BALVERSA US Full Approval -- 10 of 33 -- -- 11 of 33 -- -- 12 of 33 -- -- 13 of 33 -- -- 14 of 33 -- -- 15 of 33 -- -- 16 of 33 -- -- 17 of 33 -- ■ ■ • • • • • • • • • • • • • • • -- 18 of 33 -- • • • • • • • • • • • • • • ■ ■ -- 19 of 33 -- -- 20 of 33 -- -- 21 of 33 -- -- 22 of 33 -- -- 23 of 33 -- -- 24 of 33 -- • ➢ ➢ • ➢ ➢ ➢ -- 25 of 33 -- -- 26 of 33 -- -- 27 of 33 -- • – – – – – – • – – – – – • – • – – • – – – – – – – -- 28 of 33 -- ■ ■ • • • • • • • • • • • • • • • -- 29 of 33 -- • • • • • • • • • • • • • • ■ ■ -- 30 of 33 -- -- 31 of 33 -- -- 32 of 33 -- POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA Sum of Program Change Sum of Region Change Sum of Check Change Sum of Program Change Sum of Region Change Sum of Check Change Phase III Phase I/II P US AKEEGA (niraparib/abiraterone) P US AKEEGA (niraparib/abiraterone) P CARVYKTI (ciltacabtagene autoleucel) P TAR-200 (RIS/gemcitabine plus cetrelimab) P EU L1 Prostate cancer metastatic castration- resistant (MAGNITUDE) L1 Prostate cancer metastatic castration- resistant (MAGNITUDE) Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4) Non muscle invasive bladder cancer (SR-1 Early Data) P US TALVEY (talquetamab) TALVEY (talquetamab) P BALVERSA (erdafitinib) P TAR-210 (RIS/erdafitinib) P EU Relapsed Refractory Multiple Myeloma P EU Relapsed Refractory Multiple Myeloma Urothelial Cancer (THOR) Non Muscle Invasive Bladder Cancer (Early Data) P US ERLEADA (apalutamide) P US BALVERSA (erdafitinib) P RYBREVANT (amivantamab) P TAR-200 (RIS/gemcitabine plus cetrelimab) P EU Tablet Reduction P EU Urothelial Cancer (THOR) Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON) Non Muscle Invasive Bladder Cancer (SunRISe-1 Update) TECVAYLI (teclistamab) P US CARVYKTI (ciltacabtagene autoleucel) P IMBRUVICA (ibrutinib) P BALVERSA (erdafitinib) P EU Relapsed Refractory Multiple Myeloma Biweekly Dosing P EU Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4) Relapsed Refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO) Tumor Agnostic (RAGNAR) P US EDURANT (rilpivirine) P RYBREVANT / lazertinib RYBREVANT (amivantamab) P EU HIV pediatric 2-12 year old Non Small Cell Lung Cancer 2L (MARIPOSA-2) Solid Tumors (GIC2001) OPSUMIT (macitentan) P RYBREVANT / lazertinib P JNJ-2113 P EU Pediatric pulmonary arterial hypertension (TOMORROW) Non Small Cell Lung Cancer (MARIPOSA) Psoriasis P US OPSYNVI (macitentan/tadalafil STCT) P OPSYNVI (macitentan/tadalafil STCT) P nipocalimab P EU Pulmonary arterial hypertension Pulmonary arterial hypertension (A DUE) Rheumatoid Arthritis P US RYBREVANT (amivantamab) P SPRAVATO (esketamine) P nipocalimab P EU Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON) Treatment Resistant Major Depressive Disorder (ESCAPE-TRD) Hemolytic disease of the fetus and newborn P US RYBREVANT / lazertinib TREMFYA (guselkumab) P JNJ-5322 (BCMA/BPRC5D/CD3) P EU Non Small Cell Lung Cancer 2L (MARIPOSA-2) Crohn's Disease (GALAXI) Hematological Malignancies (Ph I Data) P US RYBREVANT / lazertinib P TREMFYA (guselkumab) P EU Non Small Cell Lung Cancer (MARIPOSA) Ulcerative Colitis Monotherapy P DARZALEX (daratumumab) Frontline multiple myeloma transplant eligible (PERSEUS) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2023* *This information is as of January 23, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. -- 33 of 33 --